cliniq QBank
Back to medications
Medication monograph

adalimumab

Monoclonal AntibodiesImmunosuppressantsDisease-modifying Antirheumatic AgentsTumor Necrosis Factor Blockers

Clinical reference

Product monograph

AMJEVITA- adalimumab-atto injection

ADALIMUMAB- adalimumab-fkjp kit

YUSIMRY- adalimumab-aqvh injection, solution

Brands & formulations

Family members

HUMIRA

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HUMIRA

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HUMIRA

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

AMGEVITA

Marketed
50 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

AMGEVITA

Marketed
50 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

AMGEVITA

Marketed
50 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HADLIMA

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HADLIMA PUSHTOUCH

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HUMIRA

Marketed
20 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HYRIMOZ

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HYRIMOZ

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HULIO

Marketed
20 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HULIO

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HULIO

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

IDACIO

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

IDACIO

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HYRIMOZ

Marketed
20 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

ABRILADA

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

ABRILADA

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

ABRILADA

Marketed
20 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

YUFLYMA

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

YUFLYMA

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

SIMLANDI

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

SIMLANDI

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

SIMLANDI

Marketed
80 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HADLIMA PUSHTOUCH

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HADLIMA

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

YUFLYMA

Marketed
80 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

YUFLYMA

Marketed
80 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HYRIMOZ

Marketed
20 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HYRIMOZ

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HYRIMOZ

Marketed
40 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HYRIMOZ

Marketed
80 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

HYRIMOZ

Marketed
80 MGSUBCUTANEOUSSOLUTION[ "adalimumab" ]
Product monograph

Classification

Chemical class
Monoclonal Antibodies
Clinical class
Immunosuppressants
Banks class
Disease-modifying Antirheumatic Agents, Tumor Necrosis Factor Blockers